S ummary A 64 year old man with refractory stage II cutaneous T‐cell lymphoma was treated with etretinate (RO109359) at 2 mg/kg/day with near clearing of nodules, plaques and pruritus in eight weeks. There were minimal side effects and no flare of his disease in five months on maintenance treatment with etretinate 1 mg/kg/day.
No takes yet. Share an insight, caveat, or question.
Wargon et al. (1984) studied this question.
Synapse has enriched 5 related papers. Consider them for comparative context: